PHC Initiates Phase I Alzheimer's Disease Trial
Posted on: Friday, 11 April 2008, 12:00 CDT
PHC has reported that its Pivotal Research Centers has initiated its largest Phase I Alzheimer's disease trial to date for a major national sponsor.
In collaboration with four prestigious neurologists, Pivotal has begun screening patients for the Phase I research effort, which is expected to have major implications for the treatment of Alzheimer patients. The first patient is expected in-house early April 2008. The Phase I activity will continue through July 2008.
The study will involve 21 randomized patients who, under close protocol, will reside in Pivotal's Phase I unit for the duration of 28 days. Pivotal Research Centers will utilize its trained and experienced Phase I staff to provide the expertise required for the compliance and success of the trial.
Bruce Shear, president and CEO of Pioneer, said: "This is the first big study since we opened our new Phase I expanded 15-bed unit this fiscal year. We anticipate this study to generate approximately $0.75 millions over the next four months and boost profits in the current quarter."
Source: Datamonitor
Related Articles
- Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
- Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
- Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study With Telaprevir in Treatment-Naive, Genotype 1 HCV Patients
- AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
- Remoxy Meets Primary Endpoint in Pivotal Phase III Study; Pain Therapeutics Expected to File NDA Q2 2008
- Patient Recruitment Completed for Pivotal Phase III Study of Remoxy; Clinical Results Expected Q4 2007
- Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
- Genzyme Begins Phase 3 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
- Preliminary Phase IIb Study Data Demonstrate Rylomine(TM) Significantly Reduces Postsurgical Orthopedic Pain
- Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients
 |
 |
User Comments (0)
RSS Feeds